- Home
- NVOS vs CVKD Comparison
NVOS vs CVKD Comparison
Compare NVOS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVOS
- CVKD
- Stock Information
- Founded
- NVOS 2000
- CVKD 2022
- Country
- NVOS United States
- CVKD United States
- Employees
- NVOS N/A
- CVKD N/A
- Industry
- NVOS Assisted Living Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- NVOS Health Care
- CVKD Health Care
- Exchange
- NVOS Nasdaq
- CVKD Nasdaq
- Market Cap
- NVOS 5.6M
- CVKD 17.1M
- IPO Year
- NVOS 2017
- CVKD 2023
- Fundamental
- Price
- NVOS $0.23
- CVKD $14.45
- Analyst Decision
- NVOS
- CVKD Strong Buy
- Analyst Count
- NVOS 0
- CVKD 2
- Target Price
- NVOS N/A
- CVKD $52.50
- AVG Volume (30 Days)
- NVOS 326.8K
- CVKD 59.6K
- Earning Date
- NVOS 12-12-2024
- CVKD 11-08-2024
- Dividend Yield
- NVOS N/A
- CVKD N/A
- EPS Growth
- NVOS N/A
- CVKD N/A
- EPS
- NVOS N/A
- CVKD N/A
- Revenue
- NVOS $13,516,958.00
- CVKD N/A
- Revenue This Year
- NVOS N/A
- CVKD N/A
- Revenue Next Year
- NVOS N/A
- CVKD N/A
- P/E Ratio
- NVOS N/A
- CVKD N/A
- Revenue Growth
- NVOS 1102.98
- CVKD N/A
- 52 Week Low
- NVOS $0.20
- CVKD $5.40
- 52 Week High
- NVOS $3.45
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- NVOS 38.13
- CVKD 56.80
- Support Level
- NVOS $0.20
- CVKD $11.19
- Resistance Level
- NVOS $0.31
- CVKD $17.95
- Average True Range (ATR)
- NVOS 0.03
- CVKD 1.37
- MACD
- NVOS 0.00
- CVKD 0.10
- Stochastic Oscillator
- NVOS 27.18
- CVKD 49.64
About NVOS Novo Integrated Sciences Inc.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.